Journal
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
Volume 286, Issue 5, Pages C998-C1008Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpcell.00357.2003
Keywords
nelfinavir; clotrimazole; barium
Categories
Funding
- NCI NIH HHS [CA-86207] Funding Source: Medline
- NCRR NIH HHS [RR-00035] Funding Source: Medline
- NICHD NIH HHS [HD-07466] Funding Source: Medline
- NIDDK NIH HHS [DK-34854, DK-57827, DK0-2729, DK-48106, DK-51056] Funding Source: Medline
Ask authors/readers for more resources
Aspartyl protease inhibitors (APIs) effectively extend the length and quality of life in human immunodeficiency virus (HIV)-infected patients, but dose-limiting side effects such as lipodystrophy, insulin resistance, and diarrhea have limited their clinical utility. Here, we show that the API nelfinavir induces a secretory form of diarrhea in HIV-infected patients. In vitro studies demonstrate that nelfinavir potentiates muscarinic stimulation of Cl- secretion by T84 human intestinal cell monolayers through amplification and prolongation of an apical membrane Ca2+ -dependent Cl- conductance. This stimulated ion secretion is associated with increased magnitude and duration of muscarinically induced intracellular Ca2+ transients via activation of a long-lived, store-operated Ca2+ entry pathway. The enhanced intracellular Ca2+ signal is associated with uncoupling of the Cl- conductance from downregulatory intracellular mediators generated normally by muscarinic activation. These data show that APIs modulate Ca2+ signaling in secretory epithelial cells and identify a novel target for treatment of clinically important API side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available